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ABSTRACT
Objectives: The early identification of patients who are being treated for low-risk gestational trophoblastic neoplasia 
(LRGTN) with single-agent chemotherapy, who are at high risk of developing chemoresistance, is of crucial importance. The 
aim of our research was to evaluate the pretreatment beta subunit of human chorionic gonadotropin (βhCG) concentration 
and its decrease after the administration of the first course of methotrexate (MTX) in predicting later chemo-resistance to 
single-agent chemotherapy. 
Material and methods: A total of 46 patients diagnosed with LRGTN treated with a 5-day methotrexate (MTX) regimen 
were retrospectively studied. 24 of the patients were successfully cured with only MTX therapy (MTX group). The disease was 
considered resistant in the remaining 22 patients who, after MTX therapy, required further chemotherapy with an EMA/CO 
regimen (EMA/CO group). To compare changes in the βhCG concentrations between the two courses of treatment (and 
the two groups), we calculated the percentage of decline. We determined the specificity and sensitivity of the initial βhCG 
level and its percentage decline, as a potential predictor of the need for a future EMA/CO regimen. For diagnostic purposes, 
βhCG levels were measured before the first and second administrations of MTX with a commercial ELISA kit. 
Results: In the EMA/CO group, we found the initial βhCG level before the first MTX dose was higher (median = 6275 mIU/mL, 
range: 21.53–192.610.0 mIU/mL) than in the MTX group (median = 532 mIU/mL, range: 56.5 mIU/mL–360.397.0 mIU/mL) 
(p = 0.034, Mann-Whitney test). The percentage decreases in the βhCG values relative to the initial concentrations were 
higher in the MTX group (median decrease = 82.7%, range: from 13.3% to 99.9%) than in the EMA/CO group (median de-
crease = 71.1%, range: from an increase of 56.1% to a decrease of 97.1%) (p = 0.0079, Mann-Whitney test). An analysis of 
the ROC curves implied optimal cutoff values for the initial βHCG (6054 IU, sensitivity = 55%, specificity = 86%) and the 
percentage change in βhCG levels (decrease by 76.5%, sensitivity = 72%, specificity = 71%). 
Conclusions: 
1. Women with initially higher βhCG levels have a greater risk of developing MTX chemo resistance.
2. It would be advantageous to consider administering an EMA/CO regimen in women with LRGTN when their initial 
βhCG levels are greater than 6000. 
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INTRODUCTION
Gestational trophoblastic neoplasm (GTN) is a highly 
curable group of malignant pathologies that develop from 
trophoblastic cells [1]. It includes placental site trophoblastic 
tumors (PSTT), invasive moles, epithelial trophoblastic tumors 
(ETT) and choriocarcinomas. In recent years, one of the big 
challenges has been to find biomarkers for gestational troph-
oblastic disease (GTD) that could significantly improve the 
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identification of patients who have a higher risk of developing 
more aggressive forms of the disease. Based on WHO criteria 
that consider epidemiological data, the course of disease has 
been qualified as either low-risk (LRGTN) or high-risk (HRGTN). 
Based on this same WHO risk-factor scoring system as modi-
fied by FIGO, patients diagnosed with GTN are classified as hav-
ing either a low-risk or a high-risk of developing methotrexate 
(MTX) resistance. The FIGO Prognostic Scoring System is also 
designed to identify patients with a high risk of developing 
aggressive GTN [2]. Clinical features included in this scoring 
system are pretreatment beta subunit of human chorionic 
gonadotropin (βhCG) levels, form of preceding pregnancy, 
time since the last pregnancy, age, size of the tumor, site of the 
spread, number of metastases, and the drugs used that failed 
to treat the tumor. Due to varying dynamics of the disease, 
this staging system does not always work perfectly in practice. 
Whereas low-risk GTN patients (who have received < 5 points) 
are treated with single-agent chemotherapy, and for high-risk 
patients (who have received >= 7 vpoints) multi-agent chem-
otherapy is recommended. βhCG, though included in the 
WHO/FIGO criteria, is not the only decisive factor in deter-
mining future management. In practice, it may happen that 
patients with a relatively high βhCG levels are still qualified as 
have a low risk of the disease. Some patients, particularly those 
with high pre-treatment βhCG levels, who are assigned to the 
LRGTN group and are thus administered with a single-agent 
chemotherapy, in fact, later, require therapy conversion. Al-
though the disease is highly sensitive to chemotherapy [3], 
early diagnosis and the best choice of treatment regimen are 
important for patients; and this may also shorten the treat-
ment time, and consequently, its costs.  If misdiagnosed at 
an early stage, malignant gestational trophoblastic disease 
may metastasize to distant organs. In addition, early diagnosis 
can permit early application of the appropriate treatment, 
which can increase the patient’s chances of a faster recovery. 
Correct diagnosis can be obtained effortlessly using analysis 
of the concentration of human chorionic gonadotropin. But 
selecting the right treatment for the patient is more compli-
cated. The application of a therapy that is too gentle can trigger 
drug resistance, whereas choosing a too-aggressive therapy 
increases the incidence of unwanted side effects and a pre-
mature disqualification of the patient from the therapy. Either 
discontinuing or disturbing treatment may also cause drug 
resistance, with the consequence of the patient remaining 
unhealed, and eventually, patient mortality. Almost 99% of 
low-risk patients respond to monotherapy, whereas 70% of 
medium-risk patients (who scored 5 and 6 points) do not re-
spond to the first-line treatment and require an adjustment of 
their treatment regimen. About 25–30% of patients with GTN 
develop resistance to the first-line chemotherapy and require 
alteration of their therapy [3]. One of the most significant steps 
in the course of a GTN resistant therapy is choosing the right 
moment to apply the triple or multi-agent regimen. Until now, 
diagnosis of resistance to single agent treatment with MTX has 
been based on the rise or stagnation of serum βhCG levels 
during treatment, and (or) development of new metastases; 
however, no consensus on a defining guideline regarding the 
diagnosis of MTX resistance has been established [4]. Also, 
initially high levels of serum βhCG are a known risk factor of 
MTX treatment failure, though its dynamics during the treat-
ment of MTX-sensitive and MTX-resistant patients still require 
some investigation. The aim of our study was to investigate 
whether initial differences in βhCG levels between the first and 
second doses of methotrexate are predictive of a future need 
for conversion to a multi-agent EMA/CO regimen.
MATERIAL AND METHODS
Patient Characteristics
A total of 46 patients diagnosed with low-risk GTN were 
retrospectively analyzed. All patients had been treated be-
tween November 2000 and September 2016 in the Depart-
ment of Gynecology, Obstetrics and Gynecologic Oncology of 
the Poznan University of Medical Sciences, which is the Polish 
Reference Center for GTD. All women were initially qualified for 
a 5-day, single-agent therapy based on the WHO criteria (25 mg 
of Methotrexate once daily, administered intramuscularly). The 
pre-treatment evaluation of each patient included a physical 
examination, measuring the serum human chorionic gonado-
tropin levels, and conducting pelvic ultrasonography and chest 
radiography. Serum βhCG levels were evaluated before each 
chemotherapy cycle. Treatment was stopped if the βhCG levels 
normalized (≤ 1 mIU/mL) (MTX group). If there was an increase, 
a plateauing or a decrease of βhCG concentrations of less 
than 15% between any of the previous and following courses 
of MTX, the therapy was converted to a multi-agent regimen. 
At some point, 22 patients were considered resistant to the 
treatment of the 5-day MTX therapy and were subsequently 
treated with an EMA/CO regimen (EMA/CO group). 
The study was conducted in accordance with the require-
ments of the Declaration of Helsinki and the study protocol 
was approved by the Ethical Review Board of the Poznan Uni-
versity of Medical Sciences, Poland (Decision No. 425/14).
Statistical  analysis
Analysis of data was performed in R programming lan-
guage (version 3.4.1) using RStudio (version 0.98.1060). 
The normality of the distribution was verified using the 
Shapiro test. Groups with a normal distribution were 
compared using the t-Student test. Groups with distribu-
tions that deviated from normal were compared using 
the Mann-Whitney test. The results were considered sig-
nificant for p values < 0.05. P values are specified in the 
figures included in this paper. Plots were generated using 
ggplot2 and ggpubr R packages. P values were calculated 
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and added to the plots using the stat_compare_means() 
function. Boxplots were generated using the geom box-
plot() function. Plot whiskers extend to the most extreme 
data point, within 1.5 times the interquartile range of 
the box. The upper and lower “hinges” correspond to the 
first and third quartiles. The central line in the boxplot 
represents the median. Dots in the plot were generated 
using the function geom_jitter() and correspond to the 
single measurements of individual patients. An R package 
plotROC was applied to produce receiver operating char-
acteristics (ROC) curves and to calculate the area under 
the curve (AUC). The cutoff values were determined using 
the OptimalCutpoints R package based on the Youden 
index. The predictive performance of the markers were 
compared using the Delong test and were computed 
using the roc.test() function from the pROC R package.
RESULTS
The range of initial βhCG concentrations in the EMA/CO 
group members equaled 21.53 mIU/mL–192.610.0 mIU/mL. 
Before conversion to the EMA/CO therapy, patients received 
between 200 and 5050mg of MTX (between 1 and 16 metho-
trexate cycles were administered, with patients receiving 
1, 2, 3, 4, 5, 7, 8 or 16 MTX courses). In the MTX group, 
24 patients received between 3 and 10 administrations 
of methotrexate (the range of initial βhCG: 56.5mIU/mL–
360.397.0 mIU/mL) and were successfully managed using 
MTX therapy (with an overall MTX dose of 375–900 mg) with-
out further conversion to an EMA/CO regimen (MTX group). 
We observed that the median of the initial βhCG lev-
els before the onset of methotrexate therapy was higher in 
the EMA/CO (median = 6275) group than in the MTX (me-
dian = 532) group (p = 0.034, Mann-Whitney test, Fig. 1). 
To analyze the initial dynamics of βhCG, we plotted the cor-
responding concentrations at the first and second doses of 
methotrexate (Fig. 2A). To compare the decrease in βhCG lev-
els between patients, we plotted the percentage change rela-
tive to the initial level at dose 1 of methotrexate (Fig. 2B). We 
observed that the average drop (the dashed line in Figure 2B) 
in the relative βhCG values was more pronounced in the MTX 
Wilcoxon, p = 0.034
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Figure 1. βhCG level at the time of diagnosis 
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group. To determine whether that difference was relevant, 
we compared the percentage change in the βhCG levels be-
tween the EMA/CO and MTX groups. We demonstrated that 
the gradient in the relative βhCG values was more negative 
in the MTX (median decrease = 82.7%, range: 13.3–99.9%) 
group than in the EMA/CO (median decrease = 71.1%, range: 
from an increase of 56.1% to a decrease of 97.1%) group 
(p = 0.0079, Mann-Whitney test, Fig. 3). To evaluate the predic-
tive value of those parameters we determined their specific-
ity and sensitivity in predicting the future need for conver-
sion to an EMA/CO regimen (Fig. 4A and 4B). An analysis of 
the ROC curves implied optimal cutoff values for the initial 
βhCG (6054 IU, sensitivity = 55%, specificity = 86%, based on 
Youden index) and the percentage change in the βhCG levels 
(a decrease of 76.5%, sensitivity = 72%, specificity = 71%, 
based on Youden index). The parameters of measuring the ini-
tial βhCG levels in comparison with the percentage changes 
in βhCG levels, and then comparing these results between the 
EMA/CO and MTX groups, showed that their predictive value 
did not differ (AUC for the initial βhCG and the percentage 
change in the βhCG levels were 0.68 and 0.74, respectively; 
DeLong test, p = 0.96). Altogether, we have shown that pa-
tients who will, in the future, be resistant to methotrexate 
and who will require an EMA/CO therapy (EMA/CO group) 
have a higher initial value of βhCG and a lower drop in the 
percentage of the βhCG value when measured between the 
first and second administrations of methotrexate.
DISCUSSION
Both defining and treating low-risk GTN remain some-
what controversial [4]. Tumor resistance is described as an in-
crease in hCG levels or their stagnation over a 2 to 3-week 
period [5], although there is no internationally accepted 
consensus on the definition of drug resistance resulting 
from chemotherapy [6]. There is also no diagnostic tool 
available to predict chemoresistance and consequently to 
establish an appropriate treatment schema at the begin-
ning of therapy. 
In our study, we focused on only one factor (the regres-
sion of βhCG levels between the first and second doses of 
methotrexate) as the prognostic indicator of methotrexate 
resistance. We aimed to evaluate whether the patients, who 
would need converting to a single-agent therapy in the 
future, have a lower decrease in their βhCG levels between 
the first and second doses of MTX administered for LRGTN. 
MTX was the first agent used and is still the most common 
drug used in the treatment of LRGTN [7]. It has already been 
shown that a 5-day schema has minimal toxicity, and this 
compares favorably with the findings of other reports using 
similar methotrexate protocols [8–11]. Therefore, we used 
a 5-day regimen of methotrexate as the initial treatment 
for low-risk GTN. We noticed that the median initial βhCG 
level prior to the onset of methotrexate therapy was higher 
in the EMA/CO group than in the MTX group. Our research 
also revealed that patients who would become resistant to 
methotrexate in the future, and therefore require EMA/CO 
therapy, have a lower percentage decrease in their βhCG 
values when measured between the first and second ad-
ministrations of methotrexate. 
Several research projects on trophoblastic disease have 
concentrated on factors associated with hCG levels before. 
In one large study, the authors described the regression of 
serum hCG levels in patients with low-risk GTN who were suc-
cessfully treated with MTX. The same authors revealed that 
serum hCG levels preceding the fourth and sixth single-agent 
chemotherapy courses proved to have excellent diagnostic 
A B
Figure 2. A. Concentrations of βhCG at the first and second doses of methotrexate B. The percentage change relative to the initial level at dose 1 
of methotrexate
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Figure 4. A. Prediction based on initial value of βhCG before methotrexate therapy B. Prediction based on percentage change in βhCG between 
cycle 1 and 2 of methotrexate therapy
Wilcoxon, p = 0.0079
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accuracy for identifying resistance to single-agent chemo-
therapy, with an area under the curve (AUC) of 0.949 and 
0.975, respectively, in the ROC curve analysis [12].
Maesta et al. [4] examined the time taken to achieve 
hCG remission in patients with low-risk postmolar GTN. 
The authors confirmed that a complete mole histology 
prior to GTN, the presence of metastatic disease, the use 
of a multi-agent therapy and a higher FIGO score were all 
independent factors associated with a longer time to hCG 
remission in patients with low-risk GTN. Chapman-Davis et 
al. [8] looked for the factors connected with resistance to 
single-agent methotrexate chemotherapy. Those authors 
described the presence of metastases, a clinicopathologic 
diagnosis of choriocarcinoma, higher FIGO/WHO scores 
and higher pretreatment hCG levels as factors associated 
with resistance to initial chemotherapy. In another research 
project, it was revealed that patients diagnosed with LRGTN 
and with a pre-treatment hCG > 400.000 IU/L should receive 
multi-agent chemotherapy (EMA/CO) from the onset of 
treatment due to a poor response to a methotrexate-folinic 
acid (MTX-FA) regimen [13]. Also, Soper et al [14], reported 
the influence of high pre-treatment hCG levels on a nega-
tive response for drug resistance, and this finding coincides 
with our own results. 
You et al. [15–17] concentrated on finding a model for 
hCG that may be useful in predicting MTX resistance. Mod-
el-building is demanding and challenging, but the authors’ 
results may have practical clinical application [17]. The NRG 
Oncology/Gynecologic Oncology Group-174 (GOG-174) 
trial showed the value of modelling the kinetic parameters 
of hCG decline regarding the resistance of the disease to 
a single-agent chemotherapy; and in fact, their results re-
vealed that their modelling could predict the individual 
risk of such resistance [15]. In an earlier study, the same 
authors confirmed that it is possible to design an individual 
model for hCG decline curves using a kinetic population ap-
proach with LRGTN patients, and that derived parameters 
were strong early predictors of MTX resistance [16]. In their 
subsequent research, the same authors confirmed the su-
perior predictive power of the kinetic population modelling 
approach. The authors showed that by using individually 
calculated modelling of the residual production of hCGres 
values, it was possible to accurately identify about 80% of 
the patients who would develop MTX resistance [17]. 
Further retrospective research based on a larger popu-
lation of patients is desired to give results that will enable 
early and adequate treatment for patients with low-risk GTN. 
Identifying the prognostic factors associated with effective 
treatment choices may help avoid unnecessary prolonga-
tion of the therapy and therefore minimize the side effects 
of chemotherapy and treatment costs and reduce patient 
anxiety. 
CONCLUSIONS
1. Women with initially higher βhCG levels have a greater 
risk of developing MTX chemo resistance.
2. It would be advantageous to consider administering 
an EMA/CO regimen in women with LRGTN when their 
initial βhCG levels are greater than 6000.
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